Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$21.10 USD
+0.21 (1.01%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $21.10 0.00 (0.00%) 6:46 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Company Summary
Miami, FL-based Summit Therapeutics is a clinical-stage biotech focused on developing novel medicinal therapies targeting oncology indications.
The lead program in the company’s pipeline is ivonescimab (SMT112 or AK112), a first-in-class bispecific antibody that targets two proteins — programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Summit is evaluating this drug in multiple late-stage studies across different settings in non-small cell lung cancer (NSCLC).
Summit is developing ivonescimab in collaboration with China-based Akeso. The company acquired an exclusive license from Akeso in 2022 to develop and ...
Company Summary
Miami, FL-based Summit Therapeutics is a clinical-stage biotech focused on developing novel medicinal therapies targeting oncology indications.
The lead program in the company’s pipeline is ivonescimab (SMT112 or AK112), a first-in-class bispecific antibody that targets two proteins — programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Summit is evaluating this drug in multiple late-stage studies across different settings in non-small cell lung cancer (NSCLC).
Summit is developing ivonescimab in collaboration with China-based Akeso. The company acquired an exclusive license from Akeso in 2022 to develop and market the drug in the United States, Canada, Europe and Japan. Management amended this collaboration agreement in June 2024, expanding its licensing deal to cover Latin America (including Mexico and all countries in Central America, South America and the Caribbean), the Middle East and Africa.
Ivonescimab is presently approved only in China (since May 2024) to treat patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI). Akeso is also evaluating the drug across multiple stages of clinical studies in different NSCLC settings and other oncology indications outside the company’s licensed territories.
Summit’s portfolio is currently devoid of any approved product. As a result, the company did not generate any revenue in 2023.
General Information
Summit Therapeutics PLC
601 BRICKELL KEY DRIVE SUITE 1000
MIAMI, FL 33131
Phone: 305-203-2034
Fax: 44-12-3544-3999
Web: http://www.summittxinc.com
Email: investors@smmttx.com
| Industry | Medical - Drugs |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 9/30/2024 |
| Exp Earnings Date | 2/18/2025 |
EPS Information
| Current Quarter EPS Consensus Estimate | -0.08 |
| Current Year EPS Consensus Estimate | -0.30 |
| Estimated Long-Term EPS Growth Rate | NA |
| Exp Earnings Date | 2/18/2025 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 20.89 |
| 52 Week High | 33.89 |
| 52 Week Low | 1.64 |
| Beta | NA |
| 20 Day Moving Average | 2,396,553.50 |
| Target Price Consensus | 34.75 |
| 4 Week | 10.53 |
| 12 Week | 87.86 |
| YTD | 700.38 |
| 4 Week | 7.98 |
| 12 Week | 72.85 |
| YTD | 543.90 |
| Shares Outstanding (millions) | 737.45 |
| Market Capitalization (millions) | 15,405.29 |
| Short Ratio | NA |
| Last Split Date | NA |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | NA |
| Change in Payout Ratio | NA |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | NA |
| Trailing 12 Months | NA |
| PEG Ratio | NA |
| vs. Previous Year (Q0/Q-4) | -166.67% |
| vs. Previous Quarter (Q0/Q-1) | -60.00% |
| vs. Previous Year (Q0/Q-4) | NA% |
| vs. Previous Quarter (Q0/Q-1) | NA% |
| Price/Book | 35.18 |
| Price/Cash Flow | NA |
| Price / Sales | NA |
| 9/30/24 | -85.42 |
| 6/30/24 | -121.21 |
| 3/31/24 | -125.07 |
| 9/30/24 | -52.66 |
| 6/30/24 | -53.69 |
| 3/31/24 | -51.02 |
| 9/30/24 | 8.31 |
| 6/30/24 | 2.35 |
| 3/31/24 | 6.97 |
| 9/30/24 | 8.31 |
| 6/30/24 | 2.35 |
| 3/31/24 | 6.97 |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | 0.59 |
| 6/30/24 | 0.27 |
| 3/31/24 | 0.06 |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | 0.00 |
| 6/30/24 | 0.00 |
| 3/31/24 | 2.26 |
| 9/30/24 | 0.00 |
| 6/30/24 | 0.00 |
| 3/31/24 | 69.34 |